Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02446600
Title Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

ovarian cancer

fallopian tube cancer

peritoneum cancer

fallopian tube serous adenocarcinoma

peritoneal carcinoma

endometrioid ovary carcinoma

peritoneal serous adenocarcinoma

fallopian tube clear cell adenocarcinoma

ovarian serous carcinoma

ovarian clear cell carcinoma

fallopian tube endometrioid adenocarcinoma

Therapies

Cediranib + Olaparib

Olaparib

Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.